Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies

An announcement from Cellectis SA ( (FR:ALCLS) ) is now available.

Cellectis has announced its financial results for the fourth quarter and fiscal year 2024, alongside a business update. The company is advancing its clinical trials, particularly UCART22 and UCART20x22, with significant regulatory designations from the FDA and European Commission, enhancing its position in the CAR T-cell therapy market. Its strategic partnership with AstraZeneca, including a $140 million investment, supports the development of next-generation genomic medicines, with a strong cash position projected to last until mid-2027.

More about Cellectis SA

Cellectis SA is a clinical-stage biotechnology company specializing in the development of innovative therapies using its TALEN® genome editing technology. The company focuses on creating treatments for serious diseases, particularly through its allogeneic CAR T-cell therapies and gene editing programs.

YTD Price Performance: -16.67%

Average Trading Volume: 950

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $95.46M

For detailed information about ALCLS stock, go to TipRanks’ Stock Analysis page.